Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Diffuse Large B-cell Lymphoma at ASH Annual Meeting
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS® (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma
UPDATE: Bull trend intact: S&P 500 rallies from the breakout point
UPDATE: Bull trend intact: S&P 500 rallies -2-
Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting
UPDATE: Bull trend intact: Charting the S&P 500's garden-variety pullback
UPDATE: Bull trend intact: Charting the S&P -2-
Health-care stocks are on a tear as demand slowly returns.
With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.
The five biotech ETFs have very different portfolios with markedly different performance.